



MUHAMMAD ARIFIN <muhammad.arifin@fk.unair.ac.id>

FW: Ticket: [#1118783] RE: [External] Re: Ticket: [#1103903] Re: Reminder: Complete the Open Access process for your article 10.1177/10732748211053927 now

6 pesan

CCX, SAGEPUP (TNQ) <ccx_sagepub@tnq.co.in>
Kepada: muhammad.arifin@fk.unair.ac.id

8 November 2021 pukul 16.04

Dear Muhammad Arifin,

As per the request, we have updated the correct corresponding email address as "muhammad.arifin@fk.unair.ac.id" in SMART.

Please let us know if there are any concerns.

Regards,

Ganesh Senthil

From: Vivek Singh [mailto:openaccess@sagepub.com]

Sent: 08 November 2021 13:58

To: ccxprod@sagepub.com

Cc: pinki.boura@sagepub.in; sage@tnq.co.in

Subject: Fwd: Ticket: [#1118783] RE: [External] Re: Ticket: [#1103903] Re: Reminder: Complete the Open Access process for your article 10.1177/10732748211053927 now

Hi Team,

Article ID- 1053927

Can you please check below email and update corresponding authors correct email address in SMART and get back to the author.

Please note authors correct email address is:

muhammad.arifin@fk.unair.ac.id

Regards

Vivek Singh

Senior Executive - Open Access

SAGE Publishing, London EC2M 2QS
www.sagepublishing.com

On Mon, 1 Nov at 11:35 AM , Bagus Sulistyono <bagus.sulistyono.1@gmail.com> wrote:

[EXTERNAL]

Dear Vivek Singh,

We have updated the corresponding email address in SMART.

Please let us know if there are any concerns.

Regards,

Ganesh Senthil

From: Vivek Singh <openaccess@sagepub.com>

Sent: 01 November 2021 15:22

To: bagus.sulistyono.1@gmail.com

Cc: arifin_ns@yahoo.com; ccxprod@sagepub.com; pinki.boura@sagepub.in; sage@tnq.co.in

Subject: [External] Re: Ticket: [#1103903] Re: Reminder: Complete the Open Access process for your article 10.1177/10732748211053927 now

Dear Bagus,

Article ID- 1053927

We sincerely apologies for the inconvenience caused.

We are again forwarding your email to the production team so they can update the correct email address.

Hi Team,

Can someone please look after authors below email and updated corresponding authors correct email address in SMART.

Regards

Vivek Singh

Senior Executive - Open Access

SAGE Publishing, London EC2M 2QS

www.sagepublishing.com

Read about what SAGE is doing to support the research and education communities during the COVID-19 pandemic [here](#).

Dear editor

We are pleased to know that the email address of our corresponding author has changed. Yet, there's still a minor correction. The email address of our corresponding author is:

muhammad.arifin@fk.unair.ac.id

We're also glad to know if there's any discount for the article processing charge, considering the APC are yet expensive for our institution in Indonesia.

Thank you.

Sincerely

Bagus Sulistyono, MD

On Fri, 29 Oct at 2:29 PM , Bagus Sulistyono <bagus.sulistyono.1@gmail.com> wrote:

Dear Editor,

Thank you for your follow up email, unfortunately latest email from openaccess, currently our corresponding author email is not changed yet, thereby we can't process the administration required.

We will process the administration as soon as our corresponding author email is changed to muhammad.arifin@fk.unair.id

Thank you

On Tue, Oct 26, 2021 at 3:57 PM Vivek Singh <openaccess@sagepub.com> wrote:

Dear Bagus,

Article ID- 1053927

Thank you for your email.

I am forwarding your email to the production team of 'Cancer Control' and they will update the correct email address in our records. Please note once you will have a response from our production team only then take actions in SAGE open access portal.

Hi Team,

Can you please check authors below email and update corresponding authors email address in our records.

Regards

Vivek Singh

Senior Executive - Open Access

SAGE Publishing, London EC2M 2QS

www.sagepublishing.com

Read about what SAGE is doing to support the research and education communities during the COVID-19 pandemic [here](#).

On Mon, 25 Oct at 12:30 PM , Bagus Sulistyono
<bagus.sulistyono.1@gmail.com> wrote:

Dear Editor,

Thank you for your reply to my email,

You had corresponding author as our request, but the **email address** used for his account is incorrect, we would like to change his email address from arifin_ns@yahoo.com to muhammad.arifin@fk.unair.id due to our institution rule for university publication.

Sincerely,

Bagus Sulistyono, MD

Bagus Sulistyono
Neurosurgery Resident
Dr. Soetomo General Hospital
Faculty of Medicine, Universitas Airlangga
Surabaya - Indonesia

On Oct 25, 2021, at 14:25, Vivek Singh
<openaccess@sagepub.com> wrote:

Dear Bagus,

Article ID- 1053927

Thank you for your email.

Please note the corresponding author has been changed as per your below request and we request the new corresponding author to visit the below link to login to our SAGE open access portal and complete the process.

<https://openaccess.sagepub.com/Article/articleprocess?article=D8ibOBoVgbw%3d&type=IS1GK4rmY7E%3d&xkey=7z0HkqG0i%2bzn3oR59b1UNA%3d%3d&linkid=n85N5%2bEBr1Q%3d>

Thank you for your email.

Regards

Vivek Singh

Senior Executive - Open Access

SAGE Publishing, London EC2M 2QS
www.sagepublishing.com

Read about what SAGE is doing to support the research and education communities during the COVID-19 pandemic [here](#).

--

Bagus Sulistyono
Neurosurgery Resident
Dr. Soetomo General Hospital
Faculty of Medicine, Universitas Airlangga
Surabaya - Indonesia

Disclaimer: The entire content of this email message, including any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you are not the named addressee or part of the entity, you should not disseminate, distribute, or copy this email. Please notify the sender immediately by e-mail if you have received this email by mistake and delete this e-mail from your system. If you are not the intended recipient you are notified that disclosing, copying, distributing, or taking any action in reliance on the contents of this information is strictly prohibited.

Disclaimer: The entire content of this email message, including any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you are not the named addressee or part of the entity, you should not disseminate, distribute, or copy this email. Please notify the sender immediately by e-mail if you have received this email by mistake and delete this e-mail from your system. If you are not the intended recipient you are notified that disclosing, copying, distributing, or taking any action in reliance on the contents of this information is strictly prohibited.

MUHAMMAD ARIFIN <muhammad.arifin@fk.unair.ac.id>
Kepada: "CCX, SAGEPUP (TNQ)" <ccx_sagepub@tnq.co.in>

9 November 2021 pukul 09.21

Dear editor

Thank you for correcting our corresponding email address to this correct email.

We're also glad to ask if there's any discount for the article processing charge, considering the APC are yet expensive for our institution in Indonesia.

Thank you.
Sincerely

M Arifin P, MD
[Kutipan teks disembunyikan]

CCX, SAGEPUP (TNQ) <ccx_sagepub@tnq.co.in>
Kepada: MUHAMMAD ARIFIN <muhammad.arifin@fk.unair.ac.id>

29 Desember 2021 pukul 10.07

Dear Dr. Muhammad Arifin,

I hope you are well. I am emailing to remind you that any corrections for your article are now due. Please check the proof link below and make sure that you send any corrections as soon as possible or let me know whether the article is approved for publication. This is to ensure timely publication of your article.

<https://sage.proofcentral.com/en-us/landing-page.html?token=4a32abc70998e422425bc090bcc3ad>

Regards,

Ganesh Senthil

[Kutipan teks disembunyikan]

[Kutipan teks disembunyikan]

CCX, SAGEPUP (TNQ) <ccx_sagepub@tnq.co.in>
Kepada: Pinki Boura <Pinki.Boura@sagepub.in>
Cc: MUHAMMAD ARIFIN <muhammad.arifin@fk.unair.ac.id>

29 Desember 2021 pukul 10.08

Dear Pinki,

Could you check and respond the below mail.

Regards,

Ganesh Senthil

From: MUHAMMAD ARIFIN [mailto:muhammad.arifin@fk.unair.ac.id]
Sent: 09 November 2021 07:51
To: CCX, SAGEPUP (TNQ)

[Kutipan teks disembunyikan]

[Kutipan teks disembunyikan]

[Kutipan teks disembunyikan]

MUHAMMAD ARIFIN <muhammad.arifin@fk.unair.ac.id>
Kepada: "CCX, SAGEPUP (TNQ)" <ccx_sagepub@tnq.co.in>

17 Februari 2022 pukul 11.52

Dear Editor

Regarding our article, we already submit our pre proof reading article for further processing, however, it's already a month but there is no confirmation nor notification from your side. Could you please inform us about our article.

Thanks & Regards

[Kutipan teks disembunyikan]

CCX, SAGEPUP (TNQ) <ccx_sagepub@tnq.co.in>
Kepada: MUHAMMAD ARIFIN <muhammad.arifin@fk.unair.ac.id>

17 Februari 2022 pukul 12.40

Dear Dr. Muhammad Arifin,

Sorry for the inconvenience.

You can disregard the below mail, Your article is currently in progress.

Please feel free to contact me if you have any further questions.

Sincerely,

Gokul Ganesh Kumaravel

Project Manager

E-mail: ccx_sagepub@tnq.co.in

SAGE Publishing

www.sagepub.com

[Kutipan teks disembunyikan]

[Kutipan teks disembunyikan]



MUHAMMAD ARIFIN <muhammad.arifin@fk.unair.ac.id>

Open access license chosen for your paper 10.1177/10732748211053927

1 pesan

openaccess@sagepub.com <openaccess@sagepub.com>

22 November 2021 pukul 07.49

Kepada: muhammad.arifin@fk.unair.ac.id, wihasto-s@fk.unair.ac.id, bagus.sulistyono.1@gmail.com, amhtamrin@gmail.com

Open access license information for your paper

Dear Authors,

Muhammad Parenrengi has selected the following open access Creative Commons license for your article, on behalf of any co-authors: [Creative Commons Attribution-NonCommercial license \(CC BY-NC 4.0\)](#)

- NIMOTUZUMAB AS ADDITIONAL THERAPY FOR GLIOMA IN PEDIATRIC AND ADOLESCENT: A SYSTEMATIC REVIEW
- 10.1177/10732748211053927
- Cancer Control

Attached is the full license and the terms of the agreement for your reference. It also specifies how your article may be reused.

Your paper will be published open access by SAGE in **Cancer Control** under the terms of this signed agreement, after payment of any article processing charge has been arranged.

Best wishes,

SAGE Publishing Open Access Team

openaccess@sagepub.com

SAGE Offices:

Los Angeles: 2455 Teller Rd Thousand Oaks, CA 91320, USA**London:** 1 Oliver's Yard, 55 City Road, London, EC1Y 1SP, UK. Registration No. 1017514**New Delhi:** B-1/I-1, Mohan Cooperative Industrial Estate, Mathura Road, Post Bag 7, New Delhi 110 044, India**Singapore:** 18 Cross Street #10-10/11/12, China Square Central, Singapore 048423**Washington, DC:** 2600 Virginia Avenue NW, Suite 600, Washington, DC, 20037, USA**Melbourne:** Level 20, 114 William Street Melbourne, VIC 3000, Australia[About SAGE](#)[Privacy policy](#)

WF2 GEA14

**10.1177_10732748211053927_License.pdf**

31K



MUHAMMAD ARIFIN <muhammad.arifin@fk.unair.ac.id>

Your article is now published online

1 pesan

SAGE Journals <noreply@sagepub.com>

22 Februari 2022 pukul 23.58

Balas Ke: noreply@sagepub.com

Kepada: muhammad.arifin@fk.unair.ac.id

Cc: sage.eprints@sagepub.com

Dear Muhammad A Parenrengi,

Thank you for publishing your article with SAGE Publishing and *Cancer Control*. Your article "Nimotuzumab as Additional Therapy for GLIOMA in Pediatric and Adolescent: A Systematic Review" is now published and is available at <https://doi.org/10.1177/10732748211053927>

For the terms of the Creative Commons open access licence selected and instructions on re-use of your article, please refer to this [page](#).

Please also visit our online resources for more information:

- [Promoting your article](#),
- [Post-publication corrections](#), and
- [Author gateway](#).

Thank you again for publishing with SAGE and *Cancer Control*. We value your feedback and encourage you to complete the brief Journal Author Survey you will receive shortly.

Best wishes,
SAGE Journals Author Services
authorproductionqueries@sagepub.com

Note: Please do not reply to this message, as replies are routed to an unmonitored mailbox. If you experience difficulty with the provided links, please check that the full link transferred to your browser without any line breaks or errant characters such as < or >. Please direct any questions to authorproductionqueries@sagepub.com, noting the article title and journal title.

You are the only recipient of this email because you are the corresponding author. Please share this email with your co-authors.